After the asteroid, the earliest bird ancestors thrived in Antarctica
After a dinosaur-killing asteroid struck the Earth near the Yucatán Peninsula in present day Mexico about 66 million years ago, about 75 percent of species on Earth eventually went extinct. However, Antarctica may have been somewhat protected because of its distance from the impact site. Fossil evidence suggests that the landmass had a temperate climate with lush vegetation, so it could have been the perfect location for the earliest members of the avian group that now includes geese and ducks.
The fossil in this new study was collected in 2011 during an expedition by the Antarctic Peninsula Paleontology Project. It is a nearly complete Vegavis iaai skull, one of the earliest known birds dating back to the latest part of the Cretaceous Period (roughly 69.2 to 68.4 million years ago). The authors generated a near-complete three-dimensional reconstruction of the new skull to study its anatomy. They found that Vegavis has a long, pointed beak and a brain shape that is considered unique among all of the known birds previously discovered from the Mesozoic Era–which includes the Triassic, Jurassic, and Cretaceous Periods. During the Mesozoic, non-avian dinosaurs and an eclectic collection of early birds such as Archaeopteryx flew in different parts of the Earth. Vegavis' long beak and brain shape place it in the group that includes all modern birds and represents the earliest evidence of birds' eventual widespread distribution across the planet.
Vegavis was first reported 20 years ago by study co-author Julia Clarke from The University of Texas at Austin and several colleagues. Initially, it was proposed as an early member of modern birds within the waterfowl group. However, modern birds are very rare in the fossil record from before the end-Cretaceous extinction, and more recent studies have shed some doubt on where Vegavis should be on the bird evolutionary tree.
'Few birds are as likely to start as many arguments among paleontologists as Vegavis,' Christopher Torres, a study co-author and paleontologist at the University of the Pacific, said in a statement. 'This new fossil is going to help resolve a lot of those arguments. Chief among them: where is Vegavis perched in the bird tree of life?'
The nearly complete skull detailed in this new study puts some of that skepticism to rest. It shows several traits including the shape of the brain and beak bones that are consistent with that of modern birds, and waterfowl specifically. One of the main differences between modern waterflow is that Vegavis' skull has traces of powerful jaw muscles that were useful for overcoming water resistance while diving to snatch fish.
Additionally, the skull features and other parts of its skeleton suggest that Vegavis used its feet for underwater propulsion while pursuing fish and other prey. This feeding strategy is more like what gerbes and loons use.
[ Related: All living birds share an 'iridescent' ancestor. ]
The known birds discovered in other parts of the planet from the late Cretaceous Period are barely recognizable by modern bird standards. Additionally, most of the sites that preserve delicate bird fossils from the Cretaceous yield specimens that are so incomplete that scientists can only get hints at their identity.
'This fossil underscores that Antarctica has much to tell us about the earliest stages of modern bird evolution,' study co-author and Ohio University paleontologist Patrick O'Connor said in a statement. 'And those few places with any substantial fossil record of Late Cretaceous birds, like Madagascar and Argentina, reveal an aviary of bizarre, now-extinct species with teeth and long bony tails, only distantly related to modern birds. Something very different seems to have been happening in the far reaches of the Southern Hemisphere, specifically in Antarctica.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
4 hours ago
- Gizmodo
Adorable Triassic Reptile Used its Freaky Back Fin to Communicate
Technological advancements have brought us many things. For paleontologists, it's introduced the ability to probe softer material—skin, feathers, scales, and hair—found on fossilized creatures. And that's resulting in some strange new findings about long-extinct animals, showing us that they're even weirder than we imagined. A paper published today in Nature offers a re-analysis of a fossilized Mirasaura grauvogeli, a 247-million-year-old reptile whose defining feature is a feather-like structure jutting out from its back. The popular conception of these features is that the appendages were feathers, but the new study argues this isn't the case. Rather, it's an unusual type of skin that stretched out like a fan from the reptile's back, the researchers argue. Further research is needed, but the study authors believe this fan likely served as a communication tool among the creatures. These structures preserved pigment-carrying particles called melanosomes that are more bird-like than reptilian. But the curious thing about these appendages is that they were neither feathers nor scales. They're 'distinctly corrugated'—much like cardboard—and were likely malleable to some extent, the researchers report in the study. 'This evidence reveals that vertebrate skin has evolutionary possibilities that are weirder than might be easily imagined,' Richard Prum, an evolutionary biologist at Yale University who wasn't involved in the new work, wrote in a commentary for Nature. 'Mirasaura teaches us that a feather is only one of the many wondrous things that reptiles evolved to grow out of their skin.' For the analysis, a team of paleontologists at Stuttgart's State Museum of Natural History, Germany, revisited an old fossil of Mirasaura discovered in 1939 and acquired by the museum in 2019. Researchers were in the dark about what the fossil even was—in fact, the team behind the new study was the one that identified the creature for the first time. Similarly, paleontologists weren't able to fully understand Mirasaura's close relative, Longisquama insignis, which also featured long, feather-like structures on its back. At the time, scientists weren't sure what to make of it at all, partly because the Longisquama fossil wasn't well preserved. For the new work, however, the team reconstructed the skeletal anatomy of the two creatures, finding it highly likely that Mirasaura and Longisquama were both part of the drepanosaur family, a strange group of reptiles from the Triassic era (between 201 million and 252 million years ago), sometimes referred to as 'monkey lizards.' And these drepanosaurs are as strange as they come: long, bird-like skulls, bodies like chameleons, and an anatomy that suggests they lived in trees. Should the new work be verified, it means that drepanosaurs may have sported elaborate, helical structures that extended out from their backs, like Mirasaura and Longisquama. When studying the past, paleontologists use their best judgment to infer physical features based on the empirical evidence. So it's even wilder that, using such careful and sophisticated methods, scientists essentially found a reptilian version of Transformers. At the same time, such 'rediscoveries' of older fossils uncover amazing insights from the past—which is why we look forward to them each time.
Newsweek
5 hours ago
- Newsweek
Cancer Vaccine Breakthrough: What We Know About 'Exciting' Early Data
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Researchers at the University of Florida are moving closer to developing what they have described as a "universal" cancer vaccine, according to a study published in Nature Biomedical Engineering on July 18. The vaccine would work by "waking the immune system up against something that looks dangerous, and then that response spills over to recognize and reject the tumor," Dr. Elias Sayour, co-author of the study, director of the Pediatric Cancer Immunotherapy Initiative, and principal investigator at the RNA Engineering Laboratory at the University of Florida, told Newsweek. Sayour said that he believed the vaccine would apply to all types of cancer, because the treatment would result in the immune system being able to "recognize and reject all forms of cancer." "In active cancers, the immune system has been fooled or lies dormant," he said. "This approach can wake it up, restoring it in the fight against cancer." Sayour said that the concept of the treatment is being investigated in ongoing clinical human trials. If all goes well, it "could be a completely new paradigm to treat all cancer patients." Photo-illustration by Newsweek/Getty Most people think of vaccines as being "preventive," and taken to "prevent or lessen the impact of certain infectious diseases," David Braun, a professor of medicine and member of the Center of Molecular and Cellular Oncology at Yale Cancer Center, told Newsweek. While there are some efforts in this field for cancer, the majority of trials investigate "therapeutic" vaccines, which are used to try to treat cancer once it develops, he said. "Most cancer vaccines try to steer the immune system to attack a patient's cancer, which makes it very difficult to create a universal vaccine," Braun, who is not associated with the study, said. Referring to the study, Braun said the research team is proposing "the idea that the vaccination itself, somewhat irrespective of what it is targeting, might stimulate the immune system enough to attack cancer." "It is a very intriguing idea, but would need to be tested very carefully in clinical studies," he added. What Does This Mean for Cancer Treatment? Almost 2 million new cancer cases were reported in the United States in 2022. In 2023, more than 600,000 people died of cancer, according to the Centers for Disease Control and Prevention (CDC) data. Cancer is the second leading cause of death in the U.S., behind heart disease. In 2022, cancer accounted for almost 19 percent of deaths in the country, according to Statista data. Cancer vaccines have been approved in the past, such as Provenge, the Seattle biotech company Dendreon's shot used to treat certain forms of advanced prostate cancer. There are also others currently undergoing the clinical trial process, such as Moderna's experimental mRNA-4157 cancer vaccine, which aims to prevent the recurrence of melanoma and lung cancer and has progressed to Phase 3 in its clinical trials. However, what makes this new study notable is the fact that it is one step closer to researchers finding a vaccine to treat all types of cancer, rather than a specific type. "This strategy could be a promising neoadjuvant therapy prior to checkpoint blockades or other cancer therapies," Hua Wang, a professor of materials science and engineering at the University of Illinois Urbana-Champaign, told Newsweek. "With more success of personalized cancer vaccines, the researchers, clinicians, and the patient community will hopefully gain more confidence in cancer vaccines," Wang, who is not associated with the study, said. "At that stage, the goal of developing a universal cancer vaccine will be more reachable." Braun deemed the study "exciting early data," but told Newsweek it still has "a long path to having a major impact on the treatment of cancers in individuals." Potential Challenges While the findings are a "promising" breakthrough in cancer research, Wang said that still "rigorous safety evaluations and the optimization for therapeutic benefits are needed before this strategy can move forward." "Generally speaking, every one of us is hoping for a universal cancer vaccine that can treat or prevent different types of cancers," he said. However, Wang added that practically, "personalized" cancer vaccines are "more likely to cross the finish line because of the higher specificity and thus less off-target effects." While many types of cancer vaccines are currently being tested in clinical trials, Wang said that the challenge largely lies in "the balance of therapeutic benefits and safety." Another key issue is that "very few researchers have the resources and support needed to push forward a clinical trial on cancer vaccine," he added. Braun also said that, while cancer vaccines hold "tremendous promise," they also raise a number of open questions. "What are the best targets for the vaccine, or are more universal vaccines possible?" he said. "In what setting would a vaccine be most effective? What other types of treatments should be given together with the vaccine?" He added that in the coming years, "it will be critical to answers these questions while also having definitive clinical studies to prove that cancer vaccines help patients to live longer." Full Interview Below Q1: What does this study mean for the general public? How could this change the prevalence and treatment of cancer? Hua Wang, a professor of materials science and engineering at the University of Illinois Urbana-Champaign: "This paper reports that the early stimulation of IFN-I pathways could increase the sensitivity of poorly-immunogenic tumors to checkpoint blockades. The researchers performed the IFN-I stimulation by using unmodified mRNAs (without a specific target). This strategy could be a promising neoadjuvant therapy prior to checkpoint blockades or other cancer therapies. However, rigorous safety evaluations and the optimization for therapeutic benefits are still needed before this strategy can move forward." David Braun, a professor of medicine and member of the Center of Molecular and Cellular Oncology at Yale Cancer Center: "This study has two important goals: (1) to understand why current immune-based treatments work so well in some patients, and (2) to try to use that knowledge to design new immune treatments. In animal models, the research team is able to make tumors more sensitivity to immune therapy using this new approach. While exciting early data, we do have to remember that this is early work in animal studies, and so there is still a long path to having a major impact on the treatment of cancers in individuals." Q2: How long do you think it will be before a universal cancer vaccine is made? Wang: "Generally speaking, every one of us is hoping for a universal cancer vaccine that can treat or prevent different types of cancers. However, practically, personalized cancer vaccines are more likely to cross the finish line because of the higher specificity and thus less off-target effects. With more success of personalized cancer vaccines, the researchers, clinicians, and the patient community will hopefully gain more confidence in cancer vaccines. At that stage, the goal of developing a universal cancer vaccine will be more reachable." Braun: "When most people think of vaccines, they think of 'preventive' vaccines—the kind that children and adults typically receive to prevent or lessen the impact of certain infectious diseases. While there are some of those efforts in cancer as well, the majority of efforts are focused on 'therapeutic' vaccines, which are used to try to treat cancer once it develops. Most cancer vaccines try to 'steer' the immune system to attack a patient's cancer, which makes it very difficult to create a universal vaccine. In this study, the research team proposes a major general form of vaccination—the idea that the vaccination itself, somewhat irrespective of what it is targeting, might stimulate the immune system enough to attack cancer. It is a very intriguing idea, but would need to be tested very carefully in clinical studies." Q3: Can you foresee any challenges in the development of a cancer vaccine? If so, what are they? Wang: "Various types of cancer vaccines including neoantigen mRNA vaccines, dendritic cell vaccines, tumor exosome vaccines, nanomaterial vaccines, and biomaterial scaffold vaccines are being tested in clinical trials at the moment. The challenge largely lies in the balance of therapeutic benefits and safety, and varies for each vaccine platform. One dramatic challenge, in my opinion, is the overwhelming bar to pursuing the clinical translation of promising cancer vaccines. Very few researchers have the resources and support needed to push forward a clinical trial on cancer vaccine." Braun: "Cancer vaccines hold tremendous promise to 'steer' the immune system to attack cancer cells, but there are a number of open questions. What are the best targets for the vaccine, or are more 'universal' vaccines possible? In what setting would a vaccine be most effective? What other types of treatments should be given together with the vaccine? In the coming years, it will be critical to answer these questions while also having definitive clinical studies to prove that cancer vaccines help patients to live longer."
Forbes
7 hours ago
- Forbes
Fungi, Carbon, And The Climate Risk Map We Missed
Abundant worldwide, most fungi are inconspicuous because of the small size of their structures, and ... More their cryptic lifestyles in soil or on dead matter. Fungi include symbionts of plants, animals, or other fungi and also parasites. They may become noticeable when fruiting, either as mushrooms or as moulds. Fungi perform an essential role in the decomposition of organic matter and have fundamental roles in nutrient cycling and exchange in the environment. The discipline of biology devoted to the study of fungi is known as mycology (from the Greek μύκης mykes, mushroom). In the past, mycology was regarded as a branch of botany, although it is now known fungi are genetically more closely related to animals than to plants. Soil fungi may not have ticker symbols but they move carbon at planetary scale, drawing an estimated 13 billion tons of CO₂ into the soil each year, equivalent to nearly a third of global fossil fuel emissions. And yet, they've been almost entirely absent from climate risk models, ESG reports, and conservation agendas. Scientists from the Society for the Protection of Underground Networks (SPUN) have released the first-ever high-resolution global maps of mycorrhizal fungal biodiversity, alongside the launch of a groundbreaking public platform called the Underground Atlas. The research, published in the journal Nature, marks the first large-scale scientific application of the global mapping initiative launched by SPUN in 2021. Built using over 2.8 billion fungal DNA sequences from 130 countries, the Atlas reveals a profound oversight: more than 90% of the planet's most diverse underground carbon ecosystems are unprotected. 'Soils store 75% of Earth's terrestrial carbon and contain ~59% of Earth's biodiversity. Yet, we've neglected to map, monitor, and protect fungal systems,' says Dr. Toby Kiers, executive director of SPUN. 'With the Underground Atlas, we're making these invisible networks visible, and therefore measurable.' The Underground Carbon Crisis Mycorrhizal fungi form vast underground networks that connect and sustain over 90% of all terrestrial plant species, channelling nutrients, supporting food systems, biodiversity, and ecosystem resilience. Critically, they also draw carbon from plants into the soil, playing a major role in carbon sequestration and climate regulation. But until now, these fungal networks have gone unmapped and unmonitored, and the implications of this are significant. 'We were surprised to learn that fungal biodiversity didn't align with traditional conservation indicators like plant richness,' says Dr. Kiers. 'That means we're missing high-value underground ecosystems that are being degraded or lost, increasing global warming and disrupting nutrient cycles.' The Atlas will also be critical in leveraging fungi to regenerate degraded ecosystems. 'Restoration practices have been dangerously incomplete because the focus has historically been on life aboveground,' said Dr. Alex Wegmann a lead scientist for The Nature Conservancy. 'These high-resolution maps provide quantitative targets for restoration managers to establish what diverse mycorrhizal communities could and should look like." Urgent action is needed to incorporate findings into international biodiversity law and policy. For example, the Ghanaian coast is a global hotspot for mycorrhizal biodiversity. But the country's coastline is eroding at roughly two meters per year and scientists are concerned that such critical biodiversity could soon be washed into the sea. To build the Underground Atlas, SPUN and partners used machine learning models trained on billions of environmental DNA sequences, geospatial data, and climate variables. For the first time, decision-makers, restoration managers, and investors can explore mycorrhizal biodiversity at a 1km² scale, enabling them to identify high-value underground ecosystems that are critical to carbon cycling, crop resilience, and biodiversity. 'This is the most data-rich global compilation of fungal eDNA ever assembled,' says Dr. Michael Van Nuland, SPUN's lead data scientist. 'There just aren't many high-resolution global maps for soil organisms, especially for ecosystem engineers like fungi.' The Atlas can make biodiversity predictions even in unsampled areas, identifying fungal richness, rarity, and degradation risk. This will enable regulators and restoration practitioners to anticipate biodiversity loss and carbon vulnerability at a landscape scale. SPUN is already working with early adopters across conservation, restoration, and legal sectors, and has observer status at the upcoming UN COP16 biodiversity summit. Implications For ESG And Restoration The new maps reveal a critical blind spot for companies and governments relying on nature-based solutions, sustainable agriculture, and biodiversity finance. 'Conservation is about protecting the systems that sustain life, and those systems don't stop at the soil surface,' says Dr. Rebecca Shaw, chief scientist at WWF. 'Healthy fungal networks are tied to higher aboveground biodiversity and greater ecosystem resilience.' Dr. Shaw says the maps should be incorporated into frameworks like the 30x30 biodiversity targets, National Biodiversity Strategies (NBSAPs), and even carbon markets. 'Much like the human gut microbiome transformed medicine, the soil microbiome is essential for planetary health,' she says. 'We must start incorporating these maps into our conservation plans, including at WWF.' She emphasizes that mycorrhizal fungi need to be recognized as a priority in the 'library of solutions' to some of the world's greatest challenges, biodiversity decline, climate change, and declining food productivity. 'They deliver powerful ecosystem services whose benefits flow directly to people. This research should help elevate the protection and restoration of fungi and their networks to the top of conservation priorities.' 'This research maps where fungal communities are thriving or under threat,' she continues. 'There is an opportunity to integrate this knowledge into decision-making about building resilience into our food systems.' These insights are also guiding restoration and corporate risk assessments. SPUN is currently piloting a project with a corporate partner to evaluate the use of mycorrhizal biodiversity assessments in material supply chains. 'This is helping us understand both the economic applications for our data and how these collaborations can contribute valuable information back to our global database,' says Dr. Van Nuland. Soil fungi aren't just climate assets, they're agricultural assets. Research shows mycelial networks can reduce nutrient leaching by up to 50% and supply up to 80% of a plant's phosphorus needs, positioning fungi as vital components of sustainable farming. Incorporating fungal biodiversity into agricultural planning offers a powerful hedge against food system risk, helping companies navigate fertilizer volatility, regulatory pressures, and the growing need to demonstrate climate-resilient practices. For businesses navigating nature risk, this may be the data layer they didn't know they needed. Soil fungi are also being considered in legal and regulatory contexts. 'Underground biodiversity is included in the Convention on Biological Diversity,' says César Rodríguez-Garavito, director of NYU's More-Than-Human Life Program. 'But in practice, policies have focused almost entirely on aboveground ecosystems.' Because fungal networks have been invisible in climate law, activities that disrupt them have gone largely unregulated, with serious consequences for carbon storage, soil health, and legal accountability. 'By making visible the presence of climate-significant soil fungi, this data can help prevent climate impacts that stem from their destruction,' he explains. A litigation toolkit is also in development with NYU Law to help Indigenous communities protect underground ecosystems threatened by extraction. Changing The Climate Narrative Beyond risk and regulation, the Underground Atlas offers something deeper: a new way of seeing and valuing ecosystems. 'Fungi have long been overlooked because they don't fit neatly into our mental models,' says Dr. Merlin Sheldrake, SPUN's director of impact and author of Entangled Life. 'These tools help us overcome that blindness and see fungi as living infrastructure.' The implications go beyond science or policy, they touch how we define intelligence, resilience and value in the natural world. While forests and coral reefs have long symbolized ecological richness, the quiet complexity of underground fungal networks has rarely captured public imagination or financial attention. That's beginning to change. 'When we understand that fungi store carbon, support biodiversity, and regulate water flows, we begin to grasp that protecting them is a matter of long-term value, not just ecological virtue.' Sheldrake argues that these maps are not just analytical tools, they are conceptual ones, helping businesses and governments see what sustainability has missed. Recognizing fungi as climate infrastructure could shift how nature is factored into risk models, insurance products, and even accounting frameworks in the years to come. Dr Van Nuland says that while the current launch represents the project's first major milestone, this is only the beginning. SPUN is currently working on more than 10 additional mapping pipelines that will expand the platform's capabilities, including maps of mycorrhizal carbon drawdown hotspots, underground threat assessments, and restoration potential analyses. 'We're only beginning to explore the economic and ecological uses of this data,' he says. 'We want to discover new applications and we're inviting researchers, funders, and policymakers to help us.' In a world increasingly focused on risk, resilience, and real assets, the lesson is clear: funghi, and the fungal networks beneath our feet, are the billion-ton blind spot we can no longer afford to ignore.
